Trial Profile
A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 02 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 02 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Feb 2023.
- 21 Sep 2021 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.